DMPK Insights #6: Protein Mass Spectrometry: Advancing the Bioanalysis of Biotherapeutics and Biomarkers
About this Podcast on Protein Mass Spectrometry
In this podcast, Scott and John will discuss the LC-MS techniques that have been applied for the bioanalysis of biotherapeutics.
The episode explores the following:
- The impact that mass spectrometry is having in the biotherapeutics and biomarker space
- The rationale behind the use of LC-MS for certain biomarkers and how sensitive LC-MS assays can be developed (and the practical limits for lower limits of quantification that can be achieved)
- Developments in mass spectrometry that are expected to benefit the analysis of biomarkers and for biotherapeutics
Capabilities
Speaker:
John Mehl – Consultant
John Mehl is currently consulting and previously worked as a director at GSK, leading the Protein MS group within the Bioanalysis, Immunogenicity and Biomarkers (BIB) department, Collegeville, PA. The group developed LC-MS assays for quantitative & qualitative analysis of biopharmaceuticals, protein & small molecule biomarkers and for the determination of in vivo protein turnover kinetics to support preclinical and clinical studies. Prior to joining GSK, John worked for BMS where he was a Sr. Principal Scientist focused on biomarker & large molecule quantification and characterization using MS. John has a PhD degree in analytical chemistry from Vanderbilt University, postdoctoral training in protein MS from MIT and an MBA in business management from Temple University. Before joining BMS, John worked for Merck in different analytical research areas including proteomics, small molecule DMPK, large molecule immunoassay method development and vaccine and biologics protein characterization, spanning both discovery and regulated laboratories. He has published extensively on the use of hybrid LC-MS for both large and small molecule quantification.
Also available on:
Stay tuned for more podcasts in our Pharmaron DMPK Insights Series!